CIBC Private Wealth Group
BMRN icon

CIBC Private Wealth Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

CIBC Private Wealth Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$38.5K Buy
648
+179
+38% +$9.74K ﹤0.01% 1892
2025
Q3 		$25.4K Buy
469
+147
+46% +$8.41K ﹤0.01% 2070
2025
Q2 		$17.7K Buy
322
+82
+34% +$4.83K ﹤0.01% 2061
2025
Q1 		$13.4K Sell
240
-356
-60% -$23.9K ﹤0.01% 2142
2024
Q4 		$40.8K Buy
596
+233
+64% +$15.6K ﹤0.01% 1755
2024
Q3 		$25.5K Hold
363
– – ﹤0.01% 2053
2024
Q2 		$30K Sell
363
-185
-34% -$15.4K ﹤0.01% 1872
2024
Q1 		$47.7K Buy
+548
New +$49.1K ﹤0.01% 1705
2023
Q1 		– Sell
-9,453
Closed -$549K – 891
2022
Q4 		$549K Sell
9,453
-47,709
-83% -$4.48M ﹤0.01% 600
2022
Q3 		$4.85M Sell
57,162
-5,113
-8% -$455K 0.01% 373
2022
Q2 		$5.16M Buy
62,275
+5
+0% +$398 0.01% 370
2022
Q1 		$4.8M Hold
62,270
– – 0.01% 403
2021
Q4 		$5.5M Hold
62,270
– – 0.01% 393
2021
Q3 		$4.81M Hold
62,270
– – 0.01% 397
2021
Q2 		$5.2M Buy
62,270
+169
+0.3% +$13.4K 0.01% 394
2021
Q1 		$4.69M Sell
62,101
-197
-0.3% -$16.1K 0.01% 403
2020
Q4 		$5.46M Buy
62,298
+17,798
+40% +$1.41M 0.01% 377
2020
Q3 		$3.39M Buy
+44,500
New +$4.5M 0.01% 399
2020
Q2 		– Sell
-28,460
Closed -$2.4M – 620
2020
Q1 		$2.4M Buy
28,460
+100
+0.4% +$8.62K 0.01% 383
2019
Q4 		$2.4M Buy
28,360
+4,731
+20% +$357K 0.01% 445
2019
Q3 		$1.59M Buy
23,629
+19
+0.1% +$1.46K 0.01% 492
2019
Q2 		$2.02M Buy
23,610
+39
+0.2% +$3.34K 0.01% 468
2019
Q1 		$2.09M Buy
23,571
+756
+3% +$70.1K 0.01% 456
2018
Q4 		$1.94M Hold
22,815
– – 0.01% 454
2018
Q3 		$2.21M Buy
22,815
+5
+0% +$499 0.01% 480
2018
Q2 		$2.15M Buy
22,810
+1,470
+7% +$129K 0.01% 477
2018
Q1 		$1.73M Sell
21,340
-6,533
-23% -$561K 0.01% 528
2017
Q4 		$2.48M Buy
27,873
+6,413
+30% +$558K 0.01% 462
2017
Q3 		$2M Buy
+21,460
New +$1.9M 0.01% 493

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIBC Private Wealth Group's BMRN Position: Q4 2025 in Review

CIBC Private Wealth Group increased its BioMarin Pharmaceuticals (BMRN) stake by 38% in Q4 2025, buying an estimated $9.74K and bringing the position to 648 shares worth $38.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1892.

CIBC Private Wealth Group first reported a position in BMRN in Q3 2017 and has held it in 29 quarters since. The position peaked at $5.5M in Q4 2021. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • CIBC Private Wealth Group held 648 shares of BioMarin Pharmaceuticals worth $38.5K as of Q4 2025.
  • CIBC Private Wealth Group bought 179 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $9.74K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #1892 holding.
  • CIBC Private Wealth Group first reported a position in BioMarin Pharmaceuticals in Q3 2017 and has held it in 29 quarters since.
  • CIBC Private Wealth Group's BioMarin Pharmaceuticals position peaked at $5.5M in Q4 2021.
  • 538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.